ArticleGland surgery2025
Machine learning-based prognostic model for metastatic breast cancer and its interpretability: a multicenter retrospective study.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prognostic evaluation of metastatic breast cancer (MBC) currently confronts a two-fold challenge: suboptimal accuracy of conventional scoring systems and insufficient clinical interpretability of machine learning models. This study aimed to construct and validate an accurate prognostic model for predicting the overall survival (OS) of patients with MBC in the Surveillance, Epidemiology, and End Results (SEER) database using machine learning (ML) techniques. Methods: A total of 1,385 MBC patients were enrolled from the SEER database and randomly assigned into the training cohort (1,035 cases) and the internal validation cohort (350 cases). An external validation cohort comprising 73 patients from Jiaxing Women and Children's Hospital was also set up. The key characteristics influencing the OS were identified through multivariate Cox regression analysis, and prognostic models were constructed using four ML algorithms. Results: The random survival forest (RSF) model achieved the best performance both in the training and internal validation cohorts, with a concordance index (C-index) of 0.723 [95% confidence interval (CI): 0.704-0.740] and 0.727 (95% CI: 0.693-0.761), respectively. Notably, the area under the curve and Brier scores of the RSF model exceeded those of other models, confirming its superior survival prediction performance. The decision curve analysis (DCA) further indicated that the RSF model could effectively predict the 1-, 3-, and 5-year OS, making it ideal for clinical application. In the external validation cohort, the C-index of the RSF model was 0.685 (95% CI: 0.606-0.758), which, although slightly lower compared with that recorded in the training cohort, was more stable. The area under the curve and Brier scores further confirmed high accuracy and calibration power of the model. The SHapley Additive exPlanations (SHAP) analysis revealed that triple-negative breast cancer (TNBC) and brain metastasis were core variables that increased mortality risk. Conclusions: The constructed RSF prognostic model demonstrated excellent predictive performance in MBC survival prediction and achieved good interpretability as confirmed by the SHAP analysis. These findings indicate that the developed model can facilitate prognostic assessment and promote the design of individualized treatments for MBC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.